We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Abcam Plc | LSE:ABC | London | Ordinary Share | GB00B6774699 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,226.00 | 1,240.00 | 1,246.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/1/2015 21:01 | Apad My only criticism of the abcam bod so far is that I had to get a biotech geek to translate the rns... | richscotsman | |
21/1/2015 20:42 | hxxp://www.cambridge | hastings | |
21/1/2015 19:43 | Maybe you can feed some jargon back, rich :-) I expect the share price to drift back - but bloody 'ell this is a good company. Should I break my 10% rule! apad | apad | |
21/1/2015 19:41 | They give grants to scientists rich …hence enthusiasm :-) However they get grants too: Firefly BioWorks received a $500,000 grant from the Massachusetts Life Science Center to further develop its multiplex platform for biomarker detection. The award was made through the Center’s Small Business Matching Grant program, which is designed to provide additional support to companies that have already received Phase 2 SBIR funding from federal agencies. Firefly says the new funds will facilitate the increase of production capacity, introduction of new products, and expansion of its team. “Our company is at an inflection point and these funds will accelerate our commercialization and the expansion of our customer base,” remarks Davide Marni, Ph.D., co-founder and CEO. Firefly is exploiting its platform technology to develop instrument-independe The entire miRNA detection process can be used directly on cell lysate and tissue digest and requires just three steps; hybridize, label, and report, Firefly explains. The hybridization step binds miRNA targets to target-specific probes attached to FirePlex hydrogel particles. Labeling ligates a universal biotinylated adapter to the captured targets, and a fluorescent reporter is then bound to the universal adapter to enable miRNA detection in a flow cytometer. One of the key features of the hydrogel particles is that they enable capture of the target molecules throughout the entire particle, not just on the surface, which Firefly claims enables expression results that are nearly independent of sample amount and generates a linear response curve below 100 attomoles of target. | apad | |
21/1/2015 19:04 | I spoke to a stem cell scientist about firefly and she seems enthused.... Mentioned the interaction of junk dna and rna being huge potential growth sectors in research... The rest of the conversation could have been double Dutch as far as I am concerned as she went into science geek babble.... Rich | richscotsman | |
21/1/2015 13:57 | funding constraints in educational and research establishments May get downgrade as they say "After an initial period of modest investment, Firefly is expected to generate attractive returns in the longer term." looks like a profit downgrade with a coat on | christmasworker | |
21/1/2015 08:28 | Strong sales imo - and now the currency is moving more in ABC's favour too. All imo/dyor etc. CR | cockneyrebel | |
21/1/2015 07:26 | Hope so, my Mum wants to buy more :-) apad | apad | |
21/1/2015 07:06 | Can see the market disappointed with todays lukewarm news Overall we expect total revenue growth for the period to be 13.8% on a constant currency basis and following the adverse rates of exchange seen during the period compared to H1 2013/14, growth on a reported basis to be 7.7%. Gross margin percentages at the product and geographic levels are expected to be broadly flat and in line with management's expectations, whilst the impact of the mix means that overall they are likely to be slightly less than those seen in the same period last year. | christmasworker | |
16/1/2015 20:31 | If anything is wrong here news wise, this will shed 200p | christmasworker | |
16/1/2015 14:31 | through resistance now richscotchman - £5 area looks the next test imo. Bit of news for you out today: Abcam inks partnership with IMCB to develop high-quality immunoassays for life science research All imo/dyor etc CR | cockneyrebel | |
16/1/2015 10:28 | i think it will hit the upward trend line anywhere around the 466 - 462 on this mini pullback and then resume its upward movement and get the next resistance around 495 IMHO | barefoot141 | |
14/1/2015 15:51 | Broken out of an up-trend resistance line - should mean a steeper rise imo: free stock charts from uk.advfn.com | cockneyrebel | |
11/1/2015 10:16 | Apad... Can't blame you for finding warmer climes.... A few trees down and a couple of slates off the roof but as it is not long since the last storm anything too flimsy was already gone! Looking forward to the trading update as ever.... Rich | richscotsman | |
09/1/2015 14:29 | trading update 16-23rd Jan in the last 3 years. CR | cockneyrebel | |
09/1/2015 10:54 | The model looks as sound as a bell, rich. It always felt right - a management type couldn't set up a business to compete. Small companies in the same niche look too risky. It seems to me that their intellectual property just gets more valuable with time - and more difficult to compete against. I've bought 11 times since 2010 and the April purchase was bigger than the previous ten put together. This tends to be my way of working - I call the portfolio a stairway and ABC is on the top step now. My rules prevent me buying more as it's now 7.5% of the portfolio. This thread's a pleasure (also quite entertaining to see CR promoting the share). Are you a rich scotsman suffering the hurricane force winds off the Hebrides, or have you moved to warmer climes? Force 12! We tend to get the fringes of those weather systems in Jersey. apad | apad | |
09/1/2015 10:10 | ..... now I am a long term investor so not too worried about peaks and troughs.... but I really do like the look of the chart just now.... must be heading into the £5-6 zone soon..... | richscotsman | |
08/1/2015 20:07 | Back to 130,000 products shipped over last 3 months today | trident5 | |
08/1/2015 19:45 | Apad... You beat me to it.... | richscotsman | |
08/1/2015 18:46 | www.businessweekly.c | apad | |
08/1/2015 15:28 | That chart is getting better and imo. CR | cockneyrebel | |
07/1/2015 11:01 | A serious international broker as Nomad now - ahead of the Jan trading update. ABCAM Plc 07 January 2015 For immediate release 7 January 2015 ABCAM PLC ("Abcam" or "the Company") Change of Adviser Abcam PLC (AIM: ABC), a global leader in the supply of life science research tools, is pleased to announce the appointment of J.P. Morgan Securities plc (which conducts its UK investment banking activities as J.P. Morgan Cazenove, "J.P. Morgan Cazenove") as the Company's nominated adviser and as joint corporate broker with immediate effect. Peel Hunt LLP will continue as joint corporate broker. | cockneyrebel |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions